Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2016

01.09.2016 | short review

ASH 2015 – stem cell transplantation

verfasst von: MD Johannes Clausen

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Hematopoietic stem cell transplantation (HSCT) remains one of the most dynamic fields in hematology, as reflected by the large number of abstracts on new developments and establishing concepts in this scientific and clinical area, presented at the ASH meeting in December 2015. The role of haploidentical transplantation for recipients lacking an HLA-matched donor was further strengthened, and the use of an intelligently designed and carefully developed concept of immunomodulation, namely posttransplant cyclophosphamide, enabling successful transplantation across the multi-antigeneic HLA-barrier. Furthermore, with the development of novel antineoplastic therapies, both effective bridging to transplant, as well as prophylactic and preemptive interventions post HSCT will help increase the overall success of increasingly complex and individualized treatment concepts. Finally, novel cellular immunotherapies, most notably the genetically engineered chimeric antigen receptor (CAR) T cell concepts, will extend the therapeutic options for patients with hematological malignancies.
Literatur
1.
Zurück zum Zitat Clausen J. ASH 2012: Allogeneic stem cell transplantation. Memo. 2013;6(3):174–6. CrossRef Clausen J. ASH 2012: Allogeneic stem cell transplantation. Memo. 2013;6(3):174–6. CrossRef
2.
Zurück zum Zitat Gaballa S, et al. Results of a two-arm phase II clinical trial using post-transplantation cyclophosphamide for prevention of graft-versus-host disease in haploidentical and mismatched unrelated donors hematopoietic stem-cell transplantation. Blood. 2015;126:152. Gaballa S, et al. Results of a two-arm phase II clinical trial using post-transplantation cyclophosphamide for prevention of graft-versus-host disease in haploidentical and mismatched unrelated donors hematopoietic stem-cell transplantation. Blood. 2015;126:152.
3.
Zurück zum Zitat Lee K‑H, et al. Allogeneic hematopoietic cell transplantation for acute myelogenous leukemia in remission – a prospective comparison of three different donor groups; matched sibling, matched unrelated, and haploidentical family donors. Blood. 2015;126:4379. CrossRef Lee K‑H, et al. Allogeneic hematopoietic cell transplantation for acute myelogenous leukemia in remission – a prospective comparison of three different donor groups; matched sibling, matched unrelated, and haploidentical family donors. Blood. 2015;126:4379. CrossRef
4.
Zurück zum Zitat Wang Y, et al. Stem-cell transplantation in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia in first complete remission: a prospective multicenter trial comparing haploidentical donors with identical sibling donors. Blood. 2015;126:62. Wang Y, et al. Stem-cell transplantation in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia in first complete remission: a prospective multicenter trial comparing haploidentical donors with identical sibling donors. Blood. 2015;126:62.
5.
Zurück zum Zitat Lorentino F, et al. HLA disparities impact on outcomes after unmanipulated haploidentical hematopoietic stem cells transplantation (HaploSCT) in acute leukemia: a study from the acute leukemia working party of the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2015;126:399. Lorentino F, et al. HLA disparities impact on outcomes after unmanipulated haploidentical hematopoietic stem cells transplantation (HaploSCT) in acute leukemia: a study from the acute leukemia working party of the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2015;126:399.
6.
Zurück zum Zitat Mussetti A, et al. Survival after T-cell replete haploidentical related donor transplant using post-transplant cyclophosphamide compared with matched unrelated donor (MUD) transplant for lymphoid malignancies. Blood. 2015;126:194. Mussetti A, et al. Survival after T-cell replete haploidentical related donor transplant using post-transplant cyclophosphamide compared with matched unrelated donor (MUD) transplant for lymphoid malignancies. Blood. 2015;126:194.
7.
Zurück zum Zitat Martinez C, et al. Alternative donors (umbilical cord blood and haploidentical donors) for allogeneic stem cell transplantation in relapsed/refractory hodgkin lymphoma: a retrospective analysis of the EBMT lymphoma working party and the spanish group of stem cell transplantation (GETH). Blood. 2015;126:4399. Martinez C, et al. Alternative donors (umbilical cord blood and haploidentical donors) for allogeneic stem cell transplantation in relapsed/refractory hodgkin lymphoma: a retrospective analysis of the EBMT lymphoma working party and the spanish group of stem cell transplantation (GETH). Blood. 2015;126:4399.
8.
Zurück zum Zitat Bertaina A, et al. Children with acute leukemia given hematopoietic stem cell transplantation (HSCT) from an HLA-compatible sibling, or an unrelated donor (UD) or an HLA-haploidentical relative after alpha/beta T-cell depletion have a comparable outcome. Blood. 2015;126:195. CrossRef Bertaina A, et al. Children with acute leukemia given hematopoietic stem cell transplantation (HSCT) from an HLA-compatible sibling, or an unrelated donor (UD) or an HLA-haploidentical relative after alpha/beta T-cell depletion have a comparable outcome. Blood. 2015;126:195. CrossRef
9.
Zurück zum Zitat Zhao Y‑L, et al. Improved Outcomes of Haploidentical Blood and Marrow Transplantation in Hematologic Malignancies: A Single Center Study of 514 Cases. Blood. 2015;126:3224. Zhao Y‑L, et al. Improved Outcomes of Haploidentical Blood and Marrow Transplantation in Hematologic Malignancies: A Single Center Study of 514 Cases. Blood. 2015;126:3224.
10.
Zurück zum Zitat Kasamon YL, et al. Nonmyeloablative (NMA), HLA-mismatched unrelated donor (mMUD) BMT with high-dose posttransplantation cyclophosphamide (PTCy) has outcomes similar to matched BMT. Blood. 2015;126:2002. Kasamon YL, et al. Nonmyeloablative (NMA), HLA-mismatched unrelated donor (mMUD) BMT with high-dose posttransplantation cyclophosphamide (PTCy) has outcomes similar to matched BMT. Blood. 2015;126:2002.
11.
Zurück zum Zitat Schlenk R, et al. Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell transplantation or high-dose cytarabine (NCT01477606). Blood. 2015;126:322. Schlenk R, et al. Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell transplantation or high-dose cytarabine (NCT01477606). Blood. 2015;126:322.
12.
Zurück zum Zitat Brunner AM, et al. Hematopoietic cell transplantation with or without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukemia in CR1. Blood. 2015;126:864. Brunner AM, et al. Hematopoietic cell transplantation with or without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukemia in CR1. Blood. 2015;126:864.
13.
Zurück zum Zitat Pratz KW, et al. Prospective study of peri-transplant use of sorafenib as remission maintenance for FLT3-ITD patients undergoing allogeneic transplantation. Blood. 2015;126:3164. Pratz KW, et al. Prospective study of peri-transplant use of sorafenib as remission maintenance for FLT3-ITD patients undergoing allogeneic transplantation. Blood. 2015;126:3164.
14.
Zurück zum Zitat Bug G, et al. Phase I/II study of the deacetylase inhibitor panobinostat as maintenance therapy after an allogeneic stem cell transplantation in patients with high-risk MDS or AML: the panobest-trial. Blood. 2015;126:4344. Bug G, et al. Phase I/II study of the deacetylase inhibitor panobinostat as maintenance therapy after an allogeneic stem cell transplantation in patients with high-risk MDS or AML: the panobest-trial. Blood. 2015;126:4344.
15.
Zurück zum Zitat Luger S, et al. Tipifarnib as maintenance therapy in acute myeloid leukemia (AML) improves survival in a subgroup of patients with high risk disease. Results of the phase III intergroup trial E2902. Blood. 2015;126:1308. Luger S, et al. Tipifarnib as maintenance therapy in acute myeloid leukemia (AML) improves survival in a subgroup of patients with high risk disease. Results of the phase III intergroup trial E2902. Blood. 2015;126:1308.
16.
Zurück zum Zitat Shipton MJ, et al. Seattle regimen RIC-HSCT in early-phase multiple myeloma: a multi-centre experience demonstrating very low treatment-related mortality and rapid graft-versus-myeloma effect associated with graft-versus-host disease. Blood. 2015;126:4355. Shipton MJ, et al. Seattle regimen RIC-HSCT in early-phase multiple myeloma: a multi-centre experience demonstrating very low treatment-related mortality and rapid graft-versus-myeloma effect associated with graft-versus-host disease. Blood. 2015;126:4355.
17.
Zurück zum Zitat Schmid C, et al. Efficacy, safety and long term results of prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia: a registry-based evaluation on 343 patients by the acute leukemia working party of EBMT. Blood. 2015;126:863. CrossRef Schmid C, et al. Efficacy, safety and long term results of prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia: a registry-based evaluation on 343 patients by the acute leukemia working party of EBMT. Blood. 2015;126:863. CrossRef
18.
Zurück zum Zitat Mehta RS, et al. Post-transplantation high dose cyclophosphamide as gvhd prophylaxis in 9/10 HLA-matched unrelated donors hematopoietic stem cell transplantation. Blood. 2015;126:3135. Mehta RS, et al. Post-transplantation high dose cyclophosphamide as gvhd prophylaxis in 9/10 HLA-matched unrelated donors hematopoietic stem cell transplantation. Blood. 2015;126:3135.
19.
Zurück zum Zitat Khoury HJ, et al. Outcomes of grades II–IV acute graft-versus-host disease post-allogeneic hematopoietic stem cell transplantation: how much progress was achieved? Blood. 2015;126:3132. Khoury HJ, et al. Outcomes of grades II–IV acute graft-versus-host disease post-allogeneic hematopoietic stem cell transplantation: how much progress was achieved? Blood. 2015;126:3132.
20.
Zurück zum Zitat Clausen J. New approaches in graft versus host disease (GvHD) management. Memo. 2016;9(1):45–7. CrossRef Clausen J. New approaches in graft versus host disease (GvHD) management. Memo. 2016;9(1):45–7. CrossRef
21.
Zurück zum Zitat Peled J, et al. The abundance of certain bacteria in the intestinal flora is associated with relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2015;126:744. Peled J, et al. The abundance of certain bacteria in the intestinal flora is associated with relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2015;126:744.
22.
Zurück zum Zitat Routy B, et al. Influence of prophylactic antibiotics aiming at gut decontamination on gastrointestinal graft-versus-host disease and overall survival following allogeneic haematopoietic stem cell transplantation. Blood. 2015;126:4319. Routy B, et al. Influence of prophylactic antibiotics aiming at gut decontamination on gastrointestinal graft-versus-host disease and overall survival following allogeneic haematopoietic stem cell transplantation. Blood. 2015;126:4319.
23.
Zurück zum Zitat Atallah E, et al. Outcome of patients 65 years and older with myelodysplastic syndrome (MDS) receiving allogeneic hematopoietic stem cell transplantation compared to patients 55–64 years of age. Blood. 2015;126:193. Atallah E, et al. Outcome of patients 65 years and older with myelodysplastic syndrome (MDS) receiving allogeneic hematopoietic stem cell transplantation compared to patients 55–64 years of age. Blood. 2015;126:193.
24.
Zurück zum Zitat Attal M, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone du Myelome (IFM/DFCI 2009 trial). Blood. 2015;126:391. Attal M, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone du Myelome (IFM/DFCI 2009 trial). Blood. 2015;126:391.
25.
Zurück zum Zitat Cook G, et al. A salvage autologous stem cell transplant (ASCT2) induces superior overall survival following bortezomib-containing re-induction therapy for relapsed multiple myeloma (MM): results from the myeloma X (intensive) trial. Blood. 2015;126:394. Cook G, et al. A salvage autologous stem cell transplant (ASCT2) induces superior overall survival following bortezomib-containing re-induction therapy for relapsed multiple myeloma (MM): results from the myeloma X (intensive) trial. Blood. 2015;126:394.
26.
Zurück zum Zitat Maude SL, et al. Efficacy and safety of humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 in children with relapsed/ refractory ALL. Blood. 2015;126:683. CrossRef Maude SL, et al. Efficacy and safety of humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 in children with relapsed/ refractory ALL. Blood. 2015;126:683. CrossRef
27.
Zurück zum Zitat Curran KJ, et al. Multi-center clinical trial of CAR T cells in pediatric/young adult patients with relapsed B-cell ALL. Blood. 2015;126:2533. CrossRef Curran KJ, et al. Multi-center clinical trial of CAR T cells in pediatric/young adult patients with relapsed B-cell ALL. Blood. 2015;126:2533. CrossRef
28.
Zurück zum Zitat Enblad G, et al. Third generation CD19-CAR T cells for relapsed and refractory lymphoma and leukemia report from the swedish phase I/IIa trial. Blood. 2015;126:1534. Enblad G, et al. Third generation CD19-CAR T cells for relapsed and refractory lymphoma and leukemia report from the swedish phase I/IIa trial. Blood. 2015;126:1534.
29.
Zurück zum Zitat Danhof S, et al. CAR-engineered T cells specific for the elotuzumab target SLAMF7 eliminate primary myeloma cells and confer selective fratricide of SLAMF7+ normal lymphocyte subsets. Blood. 2015;126:115. Danhof S, et al. CAR-engineered T cells specific for the elotuzumab target SLAMF7 eliminate primary myeloma cells and confer selective fratricide of SLAMF7+ normal lymphocyte subsets. Blood. 2015;126:115.
30.
Zurück zum Zitat Arcangeli S, et al. CAR-engineered T cells specific for the elotuzumab target SLAMF7 eliminate primary myeloma cells and confer selective fratricide of SLAMF7+ normal lymphocyte subsets. Blood. 2015;126:1359. Arcangeli S, et al. CAR-engineered T cells specific for the elotuzumab target SLAMF7 eliminate primary myeloma cells and confer selective fratricide of SLAMF7+ normal lymphocyte subsets. Blood. 2015;126:1359.
31.
Zurück zum Zitat Kebriaei P, et al. Pre-emptive donor lymphocyte infusion with CD19-directed, CAR-modified T cells infused after allogeneic hematopoietic cell transplantation for patients with advanced CD19+ malignancies. Blood. 2015;126:862. Kebriaei P, et al. Pre-emptive donor lymphocyte infusion with CD19-directed, CAR-modified T cells infused after allogeneic hematopoietic cell transplantation for patients with advanced CD19+ malignancies. Blood. 2015;126:862.
Metadaten
Titel
ASH 2015 – stem cell transplantation
verfasst von
MD Johannes Clausen
Publikationsdatum
01.09.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0276-2